Suven Life gets patents from Europe, South Korea
New Delhi: Suven Life Sciences said it has been granted a product patent by Europe and South Korea each for a new chemical entity (NCE) used in the treatment of disorders associated with neurodegenerative diseases.
These patents are valid through 2033 and 2034, respectively, the company said in a BSE filing.
"We are pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS arena, which are being developed for cognitive disorders with high unmet medical need with a huge market potential globally," Suven Life CEO Venkat Jasti said.
The granted claims of patents are being developed as therapeutic agents useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, attention deficit hyperactivity disorder (ADHD), Huntington's disease, Parkinson's and schizophrenia, it added
ADHDAlzheimer's diseaseattention deficit hyperactivity disordercognitive impairmentEuropeHuntington’s diseaseNCEneurodegenerative diseasesnew chemical entityParkinson'spatentsproduct patentschizophreniaSouth KoreaSuven LifeSuven Life SciencesVenkat Jasti
Source : PTINext Story
NO DATA FOUND
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd